Trial Profile
Intense Treatment Regimen With Intravitreal Aflibercept Injection for Refractory Neovascular Age-Related Macular Degeneration With or Without Polypoidal Choroidal Vasculopathy
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jan 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms I-TRAP
- 09 Jan 2019 Status changed from not yet recruiting to recruiting.
- 25 Jul 2018 New trial record